Medybloom

Medybloom is a South Korean biotechnology company specializing in the development of next-generation peptide therapeutics for metabolic disorders. The company's core focus is on addressing the global obesity and non-alcoholic steatohepatitis (NASH) epidemics through its proprietary long-acting peptide platform. Its lead candidate, MB-101, is a triple agonist that simultaneously targets the GLP-1, GIP, and glucagon receptors to maximize weight loss and metabolic health. By optimizing the pharmacokinetic profile of these peptides, Medybloom aims to provide potent, once-weekly treatments with improved tolerability. The company is currently advancing its pipeline toward clinical-stage development to compete in the rapidly evolving metabolic drug market.